Venetoclax and Daratumumab combination treatment demonstrates pre-clinical efficacy in mouse models of Acute Myeloid Leukemia
Abstract Acute myeloid leukemia (AML) remains an incurable malignancy despite recent advances in treatment. Recently a number of new therapies have emerged for the treatment of AML which target BCL-2 or the membrane receptor CD38. Here, we show that treatment with Venetoclax and Daratumumab combinat...
Saved in:
Main Authors: | Jayna J Mistry (Author), Charlotte Hellmich (Author), Amelia Lambert (Author), Jamie A Moore (Author), Aisha Jibril (Author), Angela Collins (Author), Kristian M Bowles (Author), Stuart A Rushworth (Author) |
---|---|
Format: | Book |
Published: |
BMC,
2021-05-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Pharmacokinetics of Venetoclax Co-Administered with Posaconazole in Patients with Acute Myeloid Leukemia
by: Simona De Gregori, et al.
Published: (2023) -
Case report: Venetoclax therapy in a boy with acute myeloid leukemia in Shwachman Diamond syndrome
by: Samuele Naviglio, et al.
Published: (2023) -
Novel Compounds Synergize With Venetoclax to Target KMT2A-Rearranged Pediatric Acute Myeloid Leukemia
by: Claudia Tregnago, et al.
Published: (2022) -
Not BCL2 mutation but dominant mutation conversation contributed to acquired venetoclax resistance in acute myeloid leukemia
by: Xiang Zhang, et al.
Published: (2021) -
Combating Acute Myeloid Leukemia via Sphingosine Kinase 1 Inhibitor-Nanomedicine Combination Therapy with Cytarabine or Venetoclax
by: Thao M. Nguyen, et al.
Published: (2024)